MiMedx Group (MDXG) AI Stock Analysis

• Market Cap: $1.03B
• Dividend Yield: N/A
• Average Volume (3M): 1.03M
• Price to Earnings (P/E): 25.4
• Beta (1Y): 0.74
• Revenue Growth: 14.77%
• EPS Growth: -58.90%
• Country: US
• Employees: 837
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.11
• Shares Outstanding: 148,102,160
• 10 Day Avg. Volume: 567,995
• 30 Day Avg. Volume: 1,030,356
• PEG Ratio: -0.84
• Price to Book (P/B): 7.32
• Price to Sales (P/S): 4.05
• P/FCF Ratio: 21.92
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 0.91
• Enterprise Value/Gross Profit: 1.10
• Enterprise Value/Ebitda: 4.65
• 1Y Price Target: $12.00
• Price Target Upside: 77.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.33
• Revenue Forecast (FY): $407.96M

• Rating: 71 Outperform
• Price Target: $7.50 ▲(11.11% Upside)

MiMedx Group's overall stock score reflects strong financial performance and positive earnings call insights, which are offset by technical analysis indicating bearish trends and moderate valuation. The company's ability to navigate upcoming Medicare reforms and manage legal expenses will be crucial for sustaining growth.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for MiMedx's products, enhancing its market position and supporting long-term business expansion.

Cash Generation

Effective cash generation provides financial flexibility for reinvestment and strategic initiatives, supporting sustained growth and stability.

Product Efficacy

Demonstrated product efficacy enhances MiMedx's competitive edge in regenerative medicine, potentially driving future sales and market share.

Negative Factors

Medicare Reimbursement Uncertainty

Regulatory changes in Medicare reimbursement could affect pricing and demand for MiMedx's products, posing risks to revenue stability.

Profit Margin Pressure

Declining profit margins suggest rising costs or pricing pressures, which could impact long-term profitability if not addressed.

Legal and Regulatory Expenses

Ongoing legal expenses can drain resources and distract management, potentially affecting operational focus and financial performance.

MiMedx Group Business Overview & Revenue Model

Company Description

MiMedx Group, Inc. (MDXG) is a biotechnology company specializing in regenerative medicine and wound care products derived from human placental tissue. The company focuses on developing and commercializing innovative solutions for the treatment of chronic and acute wounds, surgical wounds, and orthopedic conditions. MiMedx's core offerings include allograft tissue products, which are used to promote healing and tissue regeneration, primarily in the fields of orthopedics, wound care, and surgical applications.

How the Company Makes Money

MiMedx generates revenue primarily through the sale of its allograft tissue products. The company sells these products to hospitals, outpatient surgical centers, and other healthcare providers. Revenue streams are largely derived from the distribution of its advanced wound care and orthopedic solutions, with a significant emphasis on the management of chronic wounds such as diabetic foot ulcers and venous leg ulcers. MiMedx has established partnerships with various healthcare organizations and distributors, which enhance its market reach and customer base. The company's financial performance is also influenced by trends in healthcare spending, the adoption of regenerative medicine, and the regulatory environment surrounding tissue-based therapies.

MiMedx Group Financial Statement Overview

Summary

MiMedx Group demonstrates a solid financial position with consistent revenue growth and strong cash flow generation. The company has improved its balance sheet by reducing leverage and increasing equity. However, declining profit margins and past financial instability highlight areas for potential improvement. Overall, the company is on a positive trajectory but must address profitability pressures to sustain growth.

Income Statement

MiMedx Group has shown consistent revenue growth, with a notable 8.16% increase in the TTM period. The gross profit margin remains strong at 81.99%, indicating efficient cost management. However, the net profit margin has decreased from 12.16% in 2024 to 10.38% in the TTM, suggesting some pressure on profitability. The EBIT and EBITDA margins have also declined, reflecting potential operational challenges.

Balance Sheet

The company's debt-to-equity ratio has improved significantly, dropping to 0.0057 in the TTM, indicating a strong equity position and reduced leverage. Return on equity is robust at 19.18%, although it has decreased from previous years. The equity ratio stands at 74.86%, showcasing a solid capital structure. However, past periods of negative equity and high leverage pose a risk if financial conditions change.

Cash Flow

MiMedx Group's cash flow performance is strong, with a 10.58% growth in free cash flow in the TTM. The operating cash flow to net income ratio is healthy at 1.18, indicating efficient cash generation relative to profits. The free cash flow to net income ratio is stable at 1.0, suggesting that the company effectively converts its earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.01B	348.88M	321.48M	267.84M	242.02M	248.23M
Gross Profit	835.16M	288.81M	266.84M	219.53M	202.39M	208.90M
EBITDA	197.96M	65.35M	40.54M	-10.68M	-1.89M	-37.52M
Net Income	115.15M	42.42M	67.44M	-30.20M	-12.30M	-49.28M
Balance Sheet
Total Assets	318.99M	263.92M	239.05M	171.43M	187.93M	202.03M
Cash, Cash Equivalents and Short-Term Investments	142.08M	104.42M	82.00M	65.95M	87.08M	95.81M
Total Debt	18.21M	24.84M	48.10M	52.47M	53.29M	51.83M
Total Liabilities	80.04M	70.81M	96.33M	96.92M	95.35M	110.61M
Stockholders Equity	238.95M	193.11M	142.72M	74.51M	92.58M	91.42M
Cash Flow
Free Cash Flow	177.89M	64.52M	24.79M	-19.41M	-5.20M	-34.49M
Operating Cash Flow	194.32M	66.20M	26.77M	-17.89M	-1.98M	-30.26M
Investing Cash Flow	-29.15M	-9.58M	-2.15M	-2.66M	-3.40M	-4.55M
Financing Cash Flow	-12.17M	-34.20M	-8.57M	-580.00K	-3.35M	61.56M

MiMedx Group Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Neutral. The current price of 6.75 is below the 20-day moving average (MA) of 6.94, below the 50-day MA of 7.00, and below the 200-day MA of 7.00, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 50.62 is Neutral, neither overbought nor oversold. The STOCH value of 55.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MDXG.

MiMedx Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	71 Outperform	$1.03B	25.38	19.44%	―	14.77%	-58.90%
PHAR	66 Neutral	$1.16B	1,223.61	0.44%	―	26.54%	―
MAZE	59 Neutral	$2.00B	―	-36.13%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATAI	47 Neutral	$1.57B	―	―	―	―	―
ORIC	43 Neutral	$1.07B	―	-39.73%	―	―	4.29%

MiMedx Group Corporate Events

MiMedx Group Reports Record Q3 2025 Revenue Growth

MiMedx Group reported a record revenue of $114 million for the third quarter of 2025, marking a 35% increase from the previous year, driven by significant growth in its Wound and Surgical franchises. The company is preparing for potential changes in Medicare and Medicaid reimbursement rules, which it believes will stabilize the industry and benefit stakeholders, while maintaining a positive long-term outlook.